AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8067808 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine alone (750 mg immediately, followed by 500 mg 6 h later)
Number of subjects: 125
Study 8067808 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate followed by mefloquine (800 mg artesunate over 2 days, followed by 750 mg mefloquine)
Number of subjects: 125
Study 2722726 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefmetazole
Number of subjects: 89
Study 2722726 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cefoxitin
Number of subjects: 89
Study 770364 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0
Study 770364 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 30469158 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine+capecitabine or streptozotocin (both with or without mitotane)
Number of subjects: 0
Study 30469158 — intervention group
Group type: EXPERIMENTAL
Intervention: local therapies
Number of subjects: 0
Study 30469158 — intervention group
Group type: COMPARATOR
Intervention: combination of etoposide, doxorubicin and cisplatin (plus mitotane)
Number of subjects: 0
Study 30536648 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise
Number of subjects: 33
Study 30536648 — intervention group
Group type: COMPARATOR
Intervention: Control period
Number of subjects: 33
Study 27872034 — intervention group
Group type: EXPERIMENTAL
Intervention: Short answer questions
Number of subjects: 49
Study 27872034 — intervention group
Group type: EXPERIMENTAL
Intervention: Full video
Number of subjects: 49
Study 27872034 — intervention group
Group type: COMPARATOR
Intervention: Logic puzzles
Number of subjects: 49
Study 25015215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg monthly
Number of subjects: 1098
Study 25015215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg PRN
Number of subjects: 1098
Study 25015215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 2.0 mg monthly
Number of subjects: 1098
Study 25015215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 2.0 mg PRN
Number of subjects: 1098
Study 22311988 — intervention group
Group type: EXPERIMENTAL
Intervention: Family intervention to promote effective parenting
Number of subjects: 186
Study 20147739 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with possible MCI
Number of subjects: 2355
Study 20147739 — intervention group
Group type: COMPARATOR
Intervention: Cognitively normal participants
Number of subjects: 2355
Study 17635414 — intervention group
Group type: EXPERIMENTAL
Intervention: COP(ant) condition
Number of subjects: 0
Study 17635414 — intervention group
Group type: COMPARATOR
Intervention: COP(post) condition
Number of subjects: 0
Study 15309422 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacor (25 g soy protein with soy fiber and phospholipids)
Number of subjects: 121
Study 15309422 — intervention group
Group type: EXPERIMENTAL
Intervention: SuproSoy (25 g soy protein without soy fiber and phospholipids)
Number of subjects: 121
Study 15309422 — intervention group
Group type: COMPARATOR
Intervention: Placebo (25 g milk protein)
Number of subjects: 121
Study 12407532 — intervention group
Group type: COMPARATOR
Intervention: Motility (−) group
Number of subjects: 20
Study 12407532 — intervention group
Group type: COMPARATOR
Intervention: Motility (+) group
Number of subjects: 20
Study 10487488 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum total sialic acid (S‐TSA)
Number of subjects: 310
Study 10487488 — intervention group
Group type: EXPERIMENTAL
Intervention: Orosomucoid
Number of subjects: 310
Study 10487488 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptoglobin
Number of subjects: 310
Study 10487488 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha1‐antitrypsin
Number of subjects: 310
Study 10487488 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐TSA in a conditional multiple logistic regression model
Number of subjects: 310
Study 8918079 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha (3 to 6 million units of recombinant IFN-alpha 2b or lymphoblastoid IFN-alpha, given 3 times weekly for 12 to 36 weeks)
Number of subjects: 27
Study 8918079 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha (total dose above 215 MU)
Number of subjects: 27
Study 8918079 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha (treatment for at least 24 weeks)
Number of subjects: 27
Study 8918079 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha (non-genotype 1b/II HCV infection)
Number of subjects: 27
Study 2226690 — intervention group
Group type: EXPERIMENTAL
Intervention: Antagonist muscle vibration
Number of subjects: 0
Study 2226690 — intervention group
Group type: COMPARATOR
Intervention: Shortening agonist muscle vibration
Number of subjects: 0
Study 7087285 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of amino acids and glucose (39.5 g of amino acids and 200 g of glucose)
Number of subjects: 8
Study 7087285 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion (800 ml)
Number of subjects: 8
Study 7087285 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of amino acids and glucose
Number of subjects: 8
Study 7087285 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 8
Study 31559808 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban environment
Number of subjects: 7974
Study 31559808 — intervention group
Group type: COMPARATOR
Intervention: Rural environment
Number of subjects: 7974
Study 31559808 — intervention group
Group type: EXPERIMENTAL
Intervention: Both environments
Number of subjects: 7974
Study 29318862 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Chengshan (BL 57), Dachangshu (BL 25), and Erbai (EX-UE 2) for 30 min each day for 3 days after surgery
Number of subjects: 60
Study 29318862 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment after surgery (Control group)
Number of subjects: 60
Study 25601014 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromocolonoscopy with indigo carmine
Number of subjects: 78
Study 25601014 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 78
Study 25601014 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromocolonoscopy
Number of subjects: 78
Study 25601014 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromocolonoscopy plus standard colonoscopy
Number of subjects: 78
Study 23838425 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES) in ACS
Number of subjects: 2705
Study 23838425 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES) in ACS
Number of subjects: 2705
Study 23838425 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES) in SAP
Number of subjects: 2705
Study 23838425 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES) in SAP
Number of subjects: 2705
Study 22302014 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150‐600 mg/day)
Number of subjects: 356
Study 22302014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study 22302014 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 356
Study 20134142 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole prophylaxis
Number of subjects: 40
Study 20134142 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole prophylaxis
Number of subjects: 40
Study 18271232 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment at Sanyinjiao (SP 6), Fenglong (ST 40), Yinlingquan (SP 9), once a day
Number of subjects: 90
Study 18271232 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol, oral administration, twice a day, 100 mg each time
Number of subjects: 90
Study 18271232 — intervention group
Group type: COMPARATOR
Intervention: Probenecid, oral administration, twice daily, 0.25 g each time
Number of subjects: 90
Study 16324236 — intervention group
Group type: EXPERIMENTAL
Intervention: Huntington's disease patients
Number of subjects: 80
Study 16324236 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 80
Study 12196359 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly CHOP (cyclophosphamide 750 mg/m(2), doxorubicin 50 mg/m(2), vincristine 1.4 mg/m(2), prednisolone 100 mg for 5 days every 2 weeks)
Number of subjects: 70
Study 12196359 — intervention group
Group type: COMPARATOR
Intervention: Dose-escalated CHOP (cyclophosphamide 1500 mg/m(2), doxorubicin 70 mg/m(2), vincristine 1.4 mg/m(2), prednisolone 100 mg for 5 days every 3 weeks)
Number of subjects: 70
Study 9785072 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (10 mg bolus)
Number of subjects: 38
Study 9785072 — intervention group
Group type: COMPARATOR
Intervention: Morphine (1 mg bolus)
Number of subjects: 38
Study 7616027 — intervention group
Group type: EXPERIMENTAL
Intervention: Preliminary and continuous hemodialysis (HD group)
Number of subjects: 5
Study 7616027 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hemodialysis)
Number of subjects: 5
Study 2239789 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (15 g/d)
Number of subjects: 27
Study 2239789 — intervention group
Group type: COMPARATOR
Intervention: Vegetable oil placebo
Number of subjects: 27
Study 6105714 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 120
Study 6105714 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 1.0 mg
Number of subjects: 120
Study 6105714 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2.0 mg
Number of subjects: 120
Study 31168657 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab 210 mg subcutaneously monthly for 12 months, followed by denosumab 60 mg subcutaneously every 6 months for 24 months
Number of subjects: 492
Study 28078741 — intervention group
Group type: EXPERIMENTAL
Intervention: Art brut therapy program called go beyond the schizophrenia (GBTS)
Number of subjects: 0
Study 28078741 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26611765 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (omeprazole, amoxicillin, and clarithromycin) for 10 days
Number of subjects: 218
Study 26611765 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy (omeprazole, bismuth subcitrate potassium, tetracycline, and metronidazole) for 10 days
Number of subjects: 218
Study 26611765 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 218
Study 23430010 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week moderate-intensity aerobic exercise
Number of subjects: 26
Study 23430010 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 26
Study 21483019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1065
Study 21483019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1065
Study 19132781 — intervention group
Group type: EXPERIMENTAL
Intervention: milnacipran 200 mg/day
Number of subjects: 888
Study 19132781 — intervention group
Group type: EXPERIMENTAL
Intervention: milnacipran 100 mg/day
Number of subjects: 888
Study 19132781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 888
Study 19665101 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal replacements (MR) during weight loss maintenance
Number of subjects: 60
Study 19665101 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 60
Study 15748230 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose DX-9065a
Number of subjects: 402
Study 15748230 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose DX-9065a
Number of subjects: 402
Study 15748230 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 402
Study 15748230 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of DX-9065a
Number of subjects: 402
Study 12572381 — intervention group
Group type: EXPERIMENTAL
Intervention: Kesuning Granule (KSNG) 8 g, three times a day
Number of subjects: 120
Study 12572381 — intervention group
Group type: COMPARATOR
Intervention: Jinbei Tankeqing Granule (JBTKQ) 7 g, three times a day
Number of subjects: 120
Study 9892479 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (ACE inhibitor) therapy administered 48 to 72 hours postoperatively in group B (103 patients)
Number of subjects: 298
Study 9892479 — intervention group
Group type: COMPARATOR
Intervention: Control group (group A, 195 patients) continued on IABP and inotropes alone
Number of subjects: 298
Study 8558900 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for person-level covariates
Number of subjects: 15
Study 8558900 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for community-level covariates
Number of subjects: 15
Study 8558900 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported behaviors
Number of subjects: 15
Study 8558900 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief and attitude items
Number of subjects: 15
Study 2359747 — intervention group
Group type: EXPERIMENTAL
Intervention: Airstream Helmet (main filter P2)
Number of subjects: 42
Study 2359747 — intervention group
Group type: EXPERIMENTAL
Intervention: Sundström Mask (main filter P3)
Number of subjects: 42
Study 2359747 — intervention group
Group type: COMPARATOR
Intervention: No respirator
Number of subjects: 42
Study 709092 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted diet (control)
Number of subjects: 15
Study 709092 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg cholesterol diet
Number of subjects: 15
Study 709092 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg cholesterol diet
Number of subjects: 15
Study 709092 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg cholesterol diet (after 600 mg diet)
Number of subjects: 15
Study 709092 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols (3 g daily) added to 100 mg cholesterol diet
Number of subjects: 15
Study 709092 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols (3 g daily) added to 600 mg cholesterol diet
Number of subjects: 15
Study 12199394 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice amplification using the ChatterVox portable amplifier (VA, n = 15)
Number of subjects: 44
Study 12199394 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal hygiene (VH, n = 15)
Number of subjects: 44
Study 12199394 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment control group (n = 14)
Number of subjects: 44
Study 31816818 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized exercise training program based on ACE IFT model guidelines (12 weeks)
Number of subjects: 150
Study 31816818 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control group (usual lifestyle habits)
Number of subjects: 150
Study 30115422 — intervention group
Group type: EXPERIMENTAL
Intervention: DANAMI-3 participants (n=1,603)
Number of subjects: 2490
Study 30115422 — intervention group
Group type: COMPARATOR
Intervention: DANAMI-3 nonparticipants (n=887)
Number of subjects: 2490
Study 30115422 — intervention group
Group type: EXPERIMENTAL
Intervention: TMMB day 0 to 30
Number of subjects: 2490
Study 30115422 — intervention group
Group type: EXPERIMENTAL
Intervention: TMMB day 31 to 365
Number of subjects: 2490
Study 26757216 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg atomoxetine
Number of subjects: 34
Study 26757216 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg citalopram
Number of subjects: 34
Study 26757216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 25006707 — intervention group
Group type: EXPERIMENTAL
Intervention: SimDE (virtual case-based simulation)
Number of subjects: 341
Study 25006707 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 341
Study 22382254 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge letter with additional information on PPI review aligned to published guidelines
Number of subjects: 51
Study 22382254 — intervention group
Group type: COMPARATOR
Intervention: Usual practice discharge letter without additional information
Number of subjects: 51
Study 20453057 — intervention group
Group type: EXPERIMENTAL
Intervention: Information‐Motivation‐Behavioral (IMB) skills model‐based intervention
Number of subjects: 152
Study 20453057 — intervention group
Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 152
Study 17563187 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group engaged in adaptive social-cognitive processes through writing
Number of subjects: 286
Study 17563187 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 286
Study 17563187 — intervention group
Group type: EXPERIMENTAL
Intervention: Study 1 (no specific intervention mentioned)
Number of subjects: 286
Study 16401982 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited resection (segment or wedge)
Number of subjects: 0
Study 16401982 — intervention group
Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 0
Study 16401982 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited resection (intentional)
Number of subjects: 0
Study 16401982 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited resection
Number of subjects: 0
Study 12145003 — intervention group
Group type: EXPERIMENTAL
Intervention: Mono diet (40% fat; 11% saturated, 19% monounsaturated, 8% polyunsaturated fatty acids)
Number of subjects: 31
Study 12145003 — intervention group
Group type: COMPARATOR
Intervention: Poly diet (34% fat; 11% saturated, 10% monounsaturated, 10% polyunsaturated fatty acids)
Number of subjects: 31
Study 10099910 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 35
Study 10099910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 8848904 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oral promethazine (10 mg) and transdermal scopolamine (1.5 mg)
Number of subjects: 60
Study 8848904 — intervention group
Group type: COMPARATOR
Intervention: Oral diazepam (5‐15 mg)
Number of subjects: 60
Study 8848904 — intervention group
Group type: COMPARATOR
Intervention: Oral promethazine (10 mg)
Number of subjects: 60
Study 8848904 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oral promethazine and transdermal scopolamine
Number of subjects: 60
Study 8848904 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 60
Study 2193273 — intervention group
Group type: EXPERIMENTAL
Intervention: Home uterine activity monitoring with a guard ring tocodynamometer
Number of subjects: 0
Study 2193273 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine transmission of uterine activity monitoring
Number of subjects: 0
Study 2193273 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported signs and symptoms of preterm labor
Number of subjects: 0
Study 2193273 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily objective uterine activity data
Number of subjects: 0
Study 358765 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferro-Retard (100 mg ferrous sulphate)
Number of subjects: 140
Study 358765 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferro-Retard (100 mg Fe2+)
Number of subjects: 140
Study 358765 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release tablets
Number of subjects: 140
Study 358765 — intervention group
Group type: COMPARATOR
Intervention: Placebo, rapidly disintegrating and sustained release ferrous sulphate tablets
Number of subjects: 140
Study 31786869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and nimotuzumab combined with concurrent chemoradiotherapy
Number of subjects: 92
Study 31786869 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin combined with concurrent chemoradiotherapy
Number of subjects: 92
Study 30388762 — intervention group
Group type: EXPERIMENTAL
Intervention: DGA-based diet
Number of subjects: 0
Study 30388762 — intervention group
Group type: COMPARATOR
Intervention: Typical American Diet (TAD)
Number of subjects: 0
Study 25483419 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous labetalol (L)
Number of subjects: 29
Study 25483419 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydralazine (H)
Number of subjects: 29
Study 24528351 — intervention group
Group type: EXPERIMENTAL
Intervention: Photographic educational materials
Number of subjects: 76
Study 24528351 — intervention group
Group type: COMPARATOR
Intervention: List of foods
Number of subjects: 76
Study 22214231 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous adenosine
Number of subjects: 69
Study 22214231 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 69
Study 20981505 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone-poor soy (Soy-)
Number of subjects: 30
Study 20981505 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone-rich soy (Soy+)
Number of subjects: 30
Study 20981505 — intervention group
Group type: COMPARATOR
Intervention: Milk protein (Milk)
Number of subjects: 30
Study 18332608 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin treatment
Number of subjects: 117
Study 16279903 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.8 g/day mesalamine (800 mg tablet)
Number of subjects: 268
Study 16279903 — intervention group
Group type: COMPARATOR
Intervention: 2.4 g/day mesalamine (400 mg tablet)
Number of subjects: 268
Study 11477042 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing (practice visit about EBM)
Number of subjects: 132
Study 11477042 — intervention group
Group type: COMPARATOR
Intervention: Control group (visited at a later date)
Number of subjects: 132
Study 9757873 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding practices
Number of subjects: 4118
Study 8142092 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of epidural morphine
Number of subjects: 20
Study 3150126 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium Valproate (Mg VPA)
Number of subjects: 122
Study 3150126 — intervention group
Group type: COMPARATOR
Intervention: Sodium Valproate (Na VPA)
Number of subjects: 122
Study 31153497 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash-free ceramic bracket
Number of subjects: 18
Study 31153497 — intervention group
Group type: COMPARATOR
Intervention: Non-flash-free ceramic bracket
Number of subjects: 18
Study 31153497 — intervention group
Group type: COMPARATOR
Intervention: Non-flash-free metal bracket
Number of subjects: 18